ADVFN Logo ADVFN

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Scholar Rock Holdings Corporation

Scholar Rock Holdings Corporation (SRRK)

40.49
-0.36
(-0.88%)
Cerrado 11 Enero 3:00PM
40.50
0.01
(0.02%)
Fuera de horario: 6:59PM
Gráfico avanzado
Rendering Error

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Estadísticas y detalles clave

Último Precio
40.49
Postura de Compra
39.00
Postura de Venta
41.55
Volume Operado de la Acción
1,128,379
38.72 Rango del Día 40.59
6.76 Rango de 52 semanas 46.185
Capitalización de Mercado [m]
Precio Anterior
40.85
Precio de Apertura
39.45
Última hora de negociación
Volumen financiero
US$ 44,413,013
Precio Promedio Ponderado
39.36
Volumen promedio (3 m)
1,061,606
Acciones en circulación
93,614,951
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-22.86
Beneficio por acción (BPA)
-1.77
turnover
-
Beneficio neto
-165.79M

Acerca de Scholar Rock Holdings Corporation

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States.... Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States. The company's lead product candidate is SRK-015 which is a highly selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Mostrar más

Sector
Biological Pds,ex Diagnstics
Industria
Biological Pds,ex Diagnstics
Sede
Wilmington, Delaware, USA
Fundado
-
Scholar Rock Holdings Corporation is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker SRRK. The last closing price for Scholar Rock was US$40.85. Over the last year, Scholar Rock shares have traded in a share price range of US$ 6.76 to US$ 46.185.

Scholar Rock currently has 93,614,951 shares in issue. The market capitalisation of Scholar Rock is US$3.82 billion. Scholar Rock has a price to earnings ratio (PE ratio) of -22.86.

SRRK Últimas noticias

Scholar Rock Highlights 2025 Strategic Priorities

- BLA and MAA submission for apitegromab in SMA on track for 1Q 2025; if approved, U.S. launch expected in 4Q 2025 - Initiating Phase 2 OPAL clinical trial in SMA patients under two years old in...

Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious...

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other...

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other...

Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress

- Reported positive topline data from pivotal Phase 3 SAPPHIRE trial evaluating apitegromab in patients with Spinal Muscular Atrophy (SMA), achieving primary endpoint - On track to submit a U.S...

Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin

- Preclinical data show that SRK-439 increased lean mass and lowered fat mass gain in mice receiving metformin - Data support that Scholar Rock’s unique approach to selective myostatin...

Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-4.11-9.2152466367744.646.0739.7993823142.12473556CS
4-0.46-1.1233211233240.9546.1739.7998195043.15807804CS
1211.1838.143978164429.3146.18525.75106160635.97027864CS
2632.55409.9496221667.9446.1856.76137321627.10201793CS
5224.3150.09264978416.1946.1856.76111777321.81318805CS
15619.3691.623284429721.1346.1854.32572915015.750537CS
26027.55212.90571870212.94704.32560998721.41396295CS

SRRK - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Scholar Rock?
El precio actual de las acciones de Scholar Rock es US$ 40.49
¿Cuántas acciones de Scholar Rock están en circulación?
Scholar Rock tiene 93,614,951 acciones en circulación
¿Cuál es la capitalización de mercado de Scholar Rock?
La capitalización de mercado de Scholar Rock es USD 3.82B
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Scholar Rock?
Scholar Rock ha negociado en un rango de US$ 6.76 a US$ 46.185 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Scholar Rock?
El ratio precio/beneficio de Scholar Rock es -22.86
¿Cuál es la moneda de reporte de Scholar Rock?
Scholar Rock presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de Scholar Rock?
El último beneficio anual de Scholar Rock es USD -165.79M
¿Cuál es la dirección registrada de Scholar Rock?
La dirección registrada de Scholar Rock es CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Scholar Rock?
La dirección del sitio web de Scholar Rock es www.scholarrock.com
¿En qué sector industrial opera Scholar Rock?
Scholar Rock opera en el sector BIOLOGICAL PDS,EX DIAGNSTICS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
VRMEVerifyMe Inc
US$ 2.57
(52.98%)
57.83M
WKEYWISeKey International Holdings AG
US$ 10.041
(52.83%)
6.72M
DATSDatChat Inc
US$ 4.8105
(49.86%)
158.65M
CDTConduit Pharmaceuticals Inc
US$ 0.1214
(48.05%)
1.17B
INTZIntrusion Inc
US$ 2.8888
(44.44%)
40.61M
IGMSIGM Biosciences Inc
US$ 2.095
(-66.21%)
5.81M
CDTGCDT Environmental Technology Investment Holdings Ltd
US$ 1.87
(-51.30%)
2.28M
MODVModivCare Inc
US$ 6.51
(-47.88%)
2.73M
AIFUAIX Inc
US$ 0.420501
(-47.76%)
7.85M
MRSNMersana Therapeutics Inc
US$ 0.691
(-46.85%)
58.44M
CDTConduit Pharmaceuticals Inc
US$ 0.1214
(48.05%)
1.17B
NVDANVIDIA Corporation
US$ 135.91
(-3.00%)
207.53M
RGTIRigetti Computing Inc
US$ 8.9299
(-11.06%)
178.82M
VMARVision Marine Technologies Inc
US$ 2.14
(40.79%)
175.57M
DATSDatChat Inc
US$ 4.8105
(49.86%)
158.65M

SRRK Finanzas

Finanzas
Rendering Error

SRRK Discussion

Ver más
PonkenPlonken PonkenPlonken 2 semanas hace
super action
👍️0
PonkenPlonken PonkenPlonken 1 mes hace
makes new highs consistently
Triple digits on the horizon
👍️0
PonkenPlonken PonkenPlonken 1 mes hace
SRRK doing very well
almost two months since their "fake PR stunt" in SMA.
They believe this will go to market.
👍️0
PonkenPlonken PonkenPlonken 2 meses hace
this is SMA not obesity.
Super news. Have some 50 shares left ---- to the finish line
👍️0
tw0122 tw0122 2 meses hace
$38 + 30% Nov 4 Obesity national crisis.. - Scholar Rock’s industry-leading anti-myostatin portfolio includes SRK-439 and apitegromab, the first investigational anti-myostatin therapy to show improved motor function in Spinal Muscular Atrophy (SMA) in a Phase 3 trial
👍️0
Monksdream Monksdream 3 meses hace
SRRK under $30
👍️0
PonkenPlonken PonkenPlonken 3 meses hace
see the share price this week.
The people behind the $ here.... dont get fooled by this.
👍️0
PonkenPlonken PonkenPlonken 3 meses hace
over 60mn shares traded since the news were announced..... A lot of $$$. They are not "wrong"..
I really dont understand were you are coming from... Trial investigators are real and act independently.

This PR was NOT a fake stunt---- I suspect you just have a history with the stock?
👍️0
bwrbad bwrbad 3 meses hace
that not science discussion, what SOC they compared against - standard palliative care or use of current therapeutics. they omitted the latter from inclusion. they know they are miles behind Spinraza Evyrsdi Zolgensma. compared against these SRRK is baby and need to go back to table and design the right Ph4 study. FDA won't look at current data for serious consideration. the PR was a fake stunt to raise two year worth of money cheaply but wolf cry won't work they did the same before. they fooled everyone again.
👍️0
PonkenPlonken PonkenPlonken 3 meses hace
This beats the SOC and will likely replace it for years and thus generate billions in sales. 3 drugs are used for SMA, they generate 3.5bn in sales and one is for infants only. This might get 1bn in sales too.
👍️0
bwrbad bwrbad 3 meses hace
do tell more on the science in complex high level - just wait for next 2 year till they do PH4 and show better efficacy -& less massaged data
👍️0
bwrbad bwrbad 3 meses hace
SRRK Massive ????????????????? scheme
👍️0
TechandBio TechandBio 3 meses hace
The next SRRK?
BFRI 2 Million floating 5 million market cap generating money from 2 FDA approved drugs deep pipeline 60% owned by tutes and insiders Roth gave $16.00 price target a few days ago.Cash flow positive in a few quarters. micro caps are flying lately.

$srrk
👍️0
PonkenPlonken PonkenPlonken 3 meses hace
Why do you make all these claims if you dont understand the science?
The way this absorbed the offering..... should tell you a lot?

"Large bunch of lawsuits in the way" Why? You know trial investigators are real? You cant skew data in a PH3????
👍️0
bwrbad bwrbad 3 meses hace
SRRK tricky pump raised 300M for 10.6M sh dilution in last two day. next going below 7 and a large bunch of lawsuits in the way
👍️0
bwrbad bwrbad 3 meses hace
10.6M sh diluted by SRRK IN one day
👍️0
bwrbad bwrbad 3 meses hace
holy crrrrraaaap
it was mistake to buy the otherday. selling it at a small loss before it goes back to 7s. it would be futile to hold here. obviously it was a institutional and insiders created hype and fraudulent propaganda event.
👍️0
PonkenPlonken PonkenPlonken 3 meses hace
with the insiders cashing in in the high 20s like that, no one believes in new highs
They didnt believe in 30s in the first place?
👍️0
PonkenPlonken PonkenPlonken 3 meses hace
I believe you are right about all that but the market potential.

Results are not optimal, yet this beats the SOC by a mile..... It will take many years (not sure exactly) until there will be another ph3 for SMA let alone we can judge the results.

Total SOC SMA drugs are 4bn in sales combined and this one is going to capture a large chunk of it, i dont know about the infants. This might go to 50 and beyond.

👍️ 1
bwrbad bwrbad 3 meses hace
At least a year if at all approvable. srrk management stunt - questionable result and market potential.
👍️0
PonkenPlonken PonkenPlonken 3 meses hace
getting disorderly now.....
enough with the arguing
👍️0
Invest-in-America Invest-in-America 3 meses hace
SRRK: 'Monk' alerted this today --- if ya have WeBull --- at only $10. (WHO grabbed it then?? Did HE grab it??)
👍️0
Stockexpertpro Stockexpertpro 3 meses hace
SOBR 200K Float Moving Fast SRRK Wow
👍️0
tw0122 tw0122 3 meses hace
300% is a nice gain take it no regrets but if doing a daytrade be a lot more careful
👍️0
Invest-in-America Invest-in-America 3 meses hace
SRRK: And $80-per-share coming ANYWAY, despite what anyone on the Planet has to say!! (WOW!!!)



PS: And yet TRUTH-be-told, their "news" was pure STATISTICAL FLUFF!!!
👍️0
Invest-in-America Invest-in-America 3 meses hace
SRRK: As usual, TW, MONSTER DD by ya!!! (And like you just noted, if they PR a little later today about DUMPING more shares to Market to pay their outrageous bills, whelp, TOILET FLUSH in price!!!)
👍️0
PonkenPlonken PonkenPlonken 3 meses hace
short term, yes
longer term, with these results, someone will want to fund it and have a foot in the door.

A lot of offerings in issues with great data are absorbed fairly easily as in WVE as of late. It helps them finish the job.
(CADL might be a better comparison given the move)
👍️0
tw0122 tw0122 3 meses hace
SRRK they will need to do an offering so your ok .. The Company has incurred recurring losses since its inception, including net losses of $115.4 million and $77.3 million for the six months ended June 30, 2024 and 2023, respectively. In addition, the Company had an accumulated deficit of $791.8 million as of June 30, 2024. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates.
👍️0
georgie18 georgie18 3 meses hace
Good for you...I rode it years ago but have been out for a long time...🥳
👍️0
Invest-in-America Invest-in-America 3 meses hace
SRRK: I avoided this puppy, Bro, and now it has just passed JUPITER!!! (Despite its outrageous price!!)
👍️0
PonkenPlonken PonkenPlonken 3 meses hace
historical relief for patients
this EASILY beats Spinraza, Zolgensma(infants), and Evrysdi (1-1.5bn in sales each) in all the scenarios...
👍️0
Monksdream Monksdream 3 meses hace
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
tw0122 tw0122 3 meses hace
1 out of 3 patients aprox. saw some improvement.. current standard of care) at week 52
30.4% of patients receiving apitegromab had >3 point improvement in HFMSE versus 12.5% of patients on placebo
👍️0
tw0122 tw0122 3 meses hace
Open at $35 going to $20 and lower catch a dip .. Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA)

Source: Business Wire
Apitegromab met primary endpoint with statistically significant and clinically meaningful improvement in motor function as measured by the gold standard Hammersmith Functional Motor Scale Expanded (HFMSE) for patients with SMA receiving apitegromab versus placebo (current standard of care) at week 52
30.4% of patients receiving apitegromab had >3 point improvement in HFMSE versus 12.5% of patients on placebo
Patients receiving apitegromab demonstrated early motor function improvement compared to placebo from the first measured time point at 8 weeks, benefit observed at 52 weeks as measured by HFMSE
Patients receiving apitegromab experienced clinically meaningful benefit in motor function across all age groups (ages 2-21)
Favorable safety profile in SAPPHIRE consistent with apitegromab’s long-term safety profile observed in the Phase 2 TOPAZ trial with >48 months of treatment experience in SMA patients
Scholar Rock plans to submit a U.S. Biologics License Application and European Union marketing authorisation application in Q1 2025
Scholar Rock to host Investor Call today at 8:00 AM ET
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced positive topline results from the Phase 3 SAPPHIRE clinical trial (NCT05156320) evaluating the efficacy and safety of apitegromab, an investigational muscle-targeted therapy, in patients with SMA.

The study achieved its primary endpoint demonstrating a statistically significant and clinically meaningful improvement for apitegromab versus placebo in motor function as measured by the gold standard HFMSE in SMA patients on chronic dosing of standard of care therapies (either nusinersen or risdiplam). Based upon the similar pharmacological profile of the 20 mg/kg and 10 mg/kg doses of apitegromab, the statistical analysis plan was prespecified to analyze both the combined dose (10 mg/kg and 20 mg/kg) compared to placebo, and 20 mg/kg dose each compared to placebo. Statistical significance is achieved per the prespecified statistical analysis plan (Hochberg multiplicity adjustment) where the p-value (≤0.025) is more rigorous if only one prespecified analysis crosses the statistical significance boundary of ≤ 0.05.

In the main efficacy population (ages 2-12), the mean difference in change from baseline in HFMSE was 1.8 points (p=0.0192) for all patients receiving apitegromab 10 mg/kg and 20 mg/kg (n=106) compared to placebo (n=50). Patients receiving 20 mg/kg of apitegromab (n=53) showed a 1.4 point mean difference compared to placebo (p=0.1149).

The prespecified analysis of the 10 mg/kg dose showed that patients receiving 10 mg/kg of apitegromab (n=53) showed an improvement of 2.2 points (nominal p=0.0121) compared to placebo.
Based upon PK/PD data from the SAPPHIRE trial, similar levels of target engagement were observed for the 10 mg/kg and 20 mg/kg dose groups.
Motor function outcomes were meaningful and consistent across the main efficacy population and in the ages 13-21 exploratory population, favored apitegromab (n=22) compared to placebo (n=10). Thirty percent of patients receiving apitegromab had >3 point improvement in HFMSE versus 12.5% of patients on placebo. Patients receiving apitegromab demonstrated early motor function improvement compared to placebo from the first measured time point at 8 weeks, benefit expanded at 52 weeks as measured by HFMSE. Following trial completion, 98 percent of SAPPHIRE patients (185/188) enrolled in the ongoing ONYX open-label expansion study.

“We are thrilled that apitegromab met the primary endpoint in our Phase 3 SAPPHIRE clinical study. The results clearly demonstrate robust and clinically meaningful improvement in motor function in patients with SMA,” said Jay Backstrom, M.D., MPH, President and Chief Executive Officer of Scholar Rock. “At Scholar Rock, we are working with urgency to deliver the potentially transformative benefits of apitegromab to children and adults with SMA in the US, Europe, and around the world.”

Treatment with apitegromab was well-tolerated across all age groups. There were no clinically relevant differences in the adverse event profile by dose, 10 mg/kg versus 20 mg/kg. No new safety findings were observed in the SAPPHIRE clinical trial; the profile was consistent with that observed in the Phase 2 TOPAZ clinical trial, including an extension study which had over four years of treatment as of the cut-off date. Serious adverse events (SAEs) were consistent with the underlying disease and current standard of care received by patients; no SAEs were assessed as related to apitegromab. There were no study drug discontinuations due to adverse events.

“We are grateful to the families and investigators who participated in our trials. The positive Phase 3 SAPPHIRE trial, along with over 4 years of TOPAZ clinical trial data, clearly demonstrate the potentially transformative benefit of apitegromab to drive clinically meaningful improvements in motor function as measured by HFMSE in a broad SMA population, where motor function would normally be expected to generally decline over time,” said Jing Marantz, M.D., Ph.D., Chief Medical Officer at Scholar Rock. “We look forward to submitting our applications to the FDA and the EMA in Q1 2025.”

The U.S. Food and Drug Administration (FDA) has granted Fast Track, Orphan Drug, and Rare Pediatric Disease designations, and the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) and Orphan Medicinal Product designations, to apitegromab for the treatment of SMA. The Company plans to submit a U.S. Biologics License Application (BLA) and a European Union marketing authorisation application (MAA) in Q1 2025.

“It’s a great day for people living with SMA and their families. These encouraging trial results mark a critical milestone for the SMA community,” said Kenneth Hobby, President of Cure SMA. “Declining motor function and hopes for reversing losses associated with muscle weakness are significant unmet needs, impacting activities of daily living, from breathing, eating, self-care, to working and social interactions. We need an approved therapy that can support motor function and further improve daily activities for people with SMA.”

Analyses of the full Phase 3 SAPPHIRE data are ongoing, and Scholar Rock plans to present detailed results at an upcoming medical conference in early 2025. Preliminary baseline characteristics from the trial will be presented during a poster presentation at the upcoming 29th Annual Congress of the World Muscle Society on Friday, October 11, 2024, being held in Prague, Czech Republic.

Conference Call Information

Scholar Rock will hold an investor confere
👍️0
Tom turtles Tom turtles 3 meses hace
Um ..higher
👍️0
Tom turtles Tom turtles 3 meses hace
Their is a God ! Thank You....yahooooo
👍 1
Monksdream Monksdream 4 meses hace
SRRK under $10
👍️0
Monksdream Monksdream 5 meses hace
SRRK under $10
👍️0
Monksdream Monksdream 6 meses hace
SRRK under $10
👍️0
retireat40 retireat40 1 año hace
Wow. Now a $7 stock
👍️0
georgie18 georgie18 3 años hace
SRRK...$34.75...on the 100ma break...:party:
[11:57 AM]
georgie18 — 10/29/2021
SRRK...$27.34...Bullish Doji Star Reversal Pattern to the Upside as the Psar flipped Bullish...

Pincher Squeeze in play here...as the MACD Crosses Positive...Looking for a $40 Break/Hold...imo...we shall see...:party:
👍️0
georgie18 georgie18 3 años hace
SRRK...$28.45...Lets see if we can Break/Hold the Upper Band today...as the Bollie Squeeze sets up here...imo...We shall see...:party:
[4:32 AM]
georgie18 — 10/29/2021
SRRK...$27.34...Bullish Doji Star Reversal Pattern to the Upside as the Psar flipped Bullish...

Pincher Squeeze in play here...as the MACD Crosses Positive...Looking for a $40 Break/Hold...imo...we shall see...:party:
👍️0
georgie18 georgie18 3 años hace
SRRK...$27.34...Bullish Doji Star Reversal Pattern to the Upside as the Psar flipped Bullish...

Pincher Squeeze in play here...as the MACD Crosses Positive...Looking for a $40 Break/Hold...imo...we shall see...

Played this in the spring for nice profits...Back in again on this Pattern...

Chart... https://schrts.co/HtbEtPcc ...
👍️0
georgie18 georgie18 4 años hace
SRRK...$31.62...on the 50ma Break to the Upside...:party:
[6:26 AM]
georgie18 — 05/24/2021
SRRK...$28.75...Took a starter on the Bullish Harami today...:party:
👍️0
georgie18 georgie18 4 años hace
SRRK...$29.69...in the P/M...https://finance.yahoo.com/news/scholar-rock-presents-topaz-phase-113000823.html ...:party:
👍️0
stockguard stockguard 4 años hace
We`ll be back to higher highs soon.
👍️0
georgie18 georgie18 4 años hace
SRRK...$28.75...Took a starter on the Bullish Harami today...CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for apitegromab, a selective inhibitor of myostatin activation, for the treatment of patients with Spinal Muscular Atrophy (SMA). Fast Track designation is intended to facilitate the development and expedite the review of drugs to treat serious conditions and get new drugs to patients earlier. Through Fast Track, Scholar Rock is eligible to submit a rolling Biologic License Application (BLA) for apitegromab if relevant criteria are met...
👍️0
stockguard stockguard 4 años hace
Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy
https://www.businesswire.com/news/home/20210524005771/en/
👍️0
stockguard stockguard 4 años hace
Scholar Rock weakness overdone after TOPAZ results, says JPMorgan
JPMorgan analyst Anupam Rama noted that Scholar Rock shares are down about 15%, which Rama views as "overdone," after the company announced update 12-month results from the phase 2 TOPAZ study in the treatment of Type 2/3 Spinal Muscular Atrophy. The 12-month data showed relatively consistent functional benefit compared to six-month interim data reported in October, noted Rama, who added that "there were no major concerns" on the safety front. The analyst, who sees the "totality of data as a probability of success increase lever," reiterates an Overweight rating on Scholar Rock shares.
👍️0
georgie18 georgie18 4 años hace
SRRK...$48.08...Back in on the Bullish Engulfing Candle on the Overbought Retrace...Psar will flip to a Bullish Buy Position this week...

Break/Hold $52 with no topside resistance and we make a run at $75/$100 range on this Blue Skies Chart...imo...we shall see...

Chart..https://schrts.co/wGhsGXPZ

georgie18 Wednesday, 10/28/20 06:38:13 AM
Re: None 0
Post #
3
of 21
SRRK...$34.85...in the PM...on this Blue Skies Chart set up...no topside resistance here...
[6:37 AM]
georgie1808/10/2020
SRRK...$14.22...Hod...just keeps gradually moving up off my $11.29 alert...I think $31 is coming here...we shall see...

👍️0

Su Consulta Reciente

Delayed Upgrade Clock